<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142531</url>
  </required_header>
  <id_info>
    <org_study_id>AK/10-02-13/3862</org_study_id>
    <nct_id>NCT01142531</nct_id>
  </id_info>
  <brief_title>Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.</brief_title>
  <official_title>Effects of Bronchodilation on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent: Comparisons Between CT Scans Obtained Before and After Bronchodilation and Relationships With Pulmonary Function Tests.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT studies considering bronchial dimensions in chronic obstructive pulmonary disease (COPD)
      were conducted without control of bronchodilation. Some data however suggest that total lung
      capacity (CT scan is performed after full inspiration) is increased in individuals affected
      by chronic or spontaneous bronchoconstriction and may decrease after bronchodilatation.
      Furthermore, no study has assessed the effect of bronchodilation on CT scans parameters
      reflecting airway remodelling and emphysema extent in COPD patients.

      This is a prospective study whose purpose is to assess the effect of bronchodilation on lung
      CT scan and pulmonary function testing (PFT) in COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients : COPD patients aged 40 years or more, with a smoking history of &gt; 10 pack-years
      (PY) and a post-bronchodilator forced expiratory volume in one second to vital capacity ratio
      (FEV1/VC) &lt; 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory
      infection in the 4 weeks before the begin of the study, concomitant pulmonary disease
      (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active
      malignancy or malignancy of any organ system within the past 5 years.

      Procedures:

      At Visit 1, after obtaining the written informed consent of the patient, medical history,
      smoking status and patient's treatment will be collected. They will be asked to discontinue
      bronchodilator therapies as follows, such that pulmonary function tests (PFT) and CT scan
      will be initially evaluated in a medication wash-out period at Visit 2:

        -  Short acting a2 agonists and anticholinergics: 8 wash-out

        -  Long acting a2 agonists: 12h wash-out

        -  Long acting anticholinergics: 48h wash-out

        -  Theophylline preparations: 48h wash-out

        -  Antileucotrienes: 48h wash-out

      At visit 2, PFT will be performed, including vital capacity (VC), forced vital capacity
      (FVC), functional residual capacity (FRC), total lung capacity (TLC), residual volume (RV),
      forced expiratory volume in one second (FEV1), diffusion lung capacity for carbon monoxide
      (DLCO), and alveolar volume (VA) measurements (either in absolute values and percentage of
      predicted values). A first CT scan will be performed using the following technique:

        -  Supine CT scan after full inspiration.

        -  Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length) 90 quality ref mAs with
           care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm

        -  Reconstructions parameters:

      B60f 1mm-thick every 0.7 mm B20f 1mm-thick every 10.0 mm B35f 1mm-thick every 0.7 mm B60f
      5mm-thick every 5.0 mm B35f 5mm-thick every 5.0 mm

      After the initial PFT and CT scan, the patient will receive 80 µg of ipratropium bromide(=
      4X20µg Atrovent, via Metered-Dose Inhaler + spacer, 30 seconds between each dose) and 60
      minutes later, 400 µg salbutamol (=4X100 µg Ventolin).

      A second PFT will be performed 30 min after salbutamol inhalation, followed by a second CT
      Scan.

      Data analysis:

        -  Emphysema index: from B20f reconstructions, calculation of RA960 using Pulmo CT
           software.

        -  Airway index: from B60f reconstructions (1mm-thick every 0.7 mm), calculations of
           luminal area and wall area for several bronchi.

      Statistical analyses : Comparisons of CT parameters values or derived values (for example :
      wall area to airway area ratio) reflecting emphysema and airways remodelling, before and
      after bronchodilation. Correlations with PFT values and derived values.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Results of CT Thorax parameters reflecting emphysema airway remodelling</measure>
    <time_frame>4 hours</time_frame>
    <description>Data analysis:
Emphysema index: from B20f reconstructions, calculation of RA960 using Pulmo CT software.
Airway index: from B60f reconstructions (1mm-thick every 0.7 mm), calculations of luminal area and wall area for several bronchi.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Results of pulmonary function tests</measure>
    <time_frame>4 hours</time_frame>
    <description>Pulmonary function tests will be performed before and after bronchodilation:
vital capacity (VC), forced vital capacity (FVC), functional residual capacity (FRC), total lung capacity (TLC), residual volume (RV), forced expiratory volume in one second (FEV1), diffusion lung capacity for carbon monoxide</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>COPD</condition>
  <condition>CT</condition>
  <condition>Bronchodilation</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <description>COPD patients aged 40 or more, with a smoking history of &gt; 10 PY and a post-bronchodilator FEV1/VC &lt; 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chest CT scan</intervention_name>
    <description>Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
90 quality ref mAs with care-dose ON
120 kV
Pitch 1.4
Rotation time 0.33 s
Acquired images 64 x 0.6 mm</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients aged 40 or more, with a smoking history of &gt; 10 PY and a post-bronchodilator
        FEV1/VC &lt; 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory
        infection in the 4 weeks before the begin of the study, concomitant pulmonary disease
        (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active
        malignancy or malignancy of any organ system within the past 5y.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 40 or more

          -  Smoking history &gt; 10 pack-years

          -  post bronchodilator FEV1/VC &lt; 0.7

        Exclusion Criteria:

          -  COPD exacerbation or infection in the 4 weeks before the study

          -  Concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer)

          -  pulmonary resection

          -  active malignancy or malignancy of any organ system within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Alain GEVENOIS, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.H.U Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Paré PD, Hogg JC, Mishima M. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1102-8.</citation>
    <PMID>10988137</PMID>
  </reference>
  <reference>
    <citation>Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1309-15. Epub 2006 Mar 23.</citation>
    <PMID>16556695</PMID>
  </reference>
  <reference>
    <citation>Patel BD, Coxson HO, Pillai SG, Agustí AG, Calverley PM, Donner CF, Make BJ, Müller NL, Rennard SI, Vestbo J, Wouters EF, Hiorns MP, Nakano Y, Camp PG, Nasute Fauerbach PV, Screaton NJ, Campbell EJ, Anderson WH, Paré PD, Levy RD, Lake SL, Silverman EK, Lomas DA; International COPD Genetics Network. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Sep 1;178(5):500-5. doi: 10.1164/rccm.200801-059OC. Epub 2008 Jun 19.</citation>
    <PMID>18565956</PMID>
  </reference>
  <reference>
    <citation>Duranti R, Filippelli M, Bianchi R, Romagnoli I, Pellegrino R, Brusasco V, Scano G. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest. 2002 Dec;122(6):2009-14.</citation>
    <PMID>12475840</PMID>
  </reference>
  <reference>
    <citation>Pellegrino R, Brusasco V. On the causes of lung hyperinflation during bronchoconstriction. Eur Respir J. 1997 Feb;10(2):468-75. Review.</citation>
    <PMID>9042651</PMID>
  </reference>
  <reference>
    <citation>Stănescu DC, Rodenstein D, Cauberghs M, Van de Woestijne KP. Failure of body plethysmography in bronchial asthma. J Appl Physiol Respir Environ Exerc Physiol. 1982 Apr;52(4):939-48.</citation>
    <PMID>7085427</PMID>
  </reference>
  <reference>
    <citation>Berger P, Perot V, Desbarats P, Tunon-de-Lara JM, Marthan R, Laurent F. Airway wall thickness in cigarette smokers: quantitative thin-section CT assessment. Radiology. 2005 Jun;235(3):1055-64. Epub 2005 Apr 15.</citation>
    <PMID>15833982</PMID>
  </reference>
  <reference>
    <citation>Orlandi I, Moroni C, Camiciottoli G, Bartolucci M, Pistolesi M, Villari N, Mascalchi M. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology. 2005 Feb;234(2):604-10.</citation>
    <PMID>15671010</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Maxime HACKX</investigator_full_name>
    <investigator_title>Maxime HACKX, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Airway Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

